Zarina Sharalaya
Interventional Cardiology · Frisco, TXNPI 1871913566
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 53.6% of the total. 2025 is the largest year on record at $15,701, more than ten times the $536 reported in 2019.
Across 210 payments — averaging $130.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Inari Medical, Inc.$4K
- Abiomed$2K
- Boston Scientific$2K
- Edwards Lifesciences$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$784
- plus $3K from 24 others
Across 11 payments — averaging $285.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Medtronic$1K
What the payments were for
- Speaking & faculty fees$12,05044%
- Grants$1,6416%
- Travel & lodging$4,61317%
- Food & beverage$9,09033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 62 | $14,687 |
| Inari Medical, Inc. | 15 | $3,844 |
| Abiomed | 35 | $1,987 |
| Boston Scientific | 6 | $1,806 |
| Edwards Lifesciences | 13 | $1,680 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $784 |
| Stryker | 11 | $725 |
| Cordis US CORP. | 3 | $554 |
| Shockwave Medical, Inc | 2 | $139 |
| Teleflex LLC | 2 | $136 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $117 |
| Biotronik Inc. | 1 | $110 |
| Heartflow, Inc. | 1 | $102 |
| Pfizer | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 3 | $88 |
| Cvrx, Inc. | 3 | $82 |
| Kestra Medical Technology Services, Inc. | 3 | $73 |
| W. L. Gore & Associates, Inc. | 3 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $53 |
| Acist Medical Systems, Inc. | 1 | $39 |
| Novartis | 2 | $36 |
| Novo Nordisk | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Abbott | 1 | $21 |
| Cardiovascular Systems Inc. | 2 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Recor Medical Inc | 1 | $17 |
| Itamar Medical Inc | 1 | $15 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$12,978
- FLOWTRIEVER CATHETER, S$3,874
- CT THROMBECTOMY SYSTEM KIT$3,874
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,120
- GENERAL - STRUCTURAL HEART$1,105
- Impella$1,039
- GENERAL ATHERECTOMY$536
- SELUTION SLR PTCA$454
- GUIDELINER$131
- ELUVIA$125
- Vascular Lithotripsy$117
- LifeVest$116
- BioMonitor$110
- FFRct$102
How this compares
$27,394 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $55,002 |
| EntrestoSacubitril/Valsartan | 24 | $19,145 |
| BrilintaTicagrelor | 11 | $6,605 |
| Losartan Potassium | 99 | $1,143 |
| Bumetanide | 22 | $1,036 |
| ClopidogrelClopidogrel Bisulfate | 82 | $836 |
| Atorvastatin Calcium | 84 | $675 |
| Metoprolol Succinate | 39 | $623 |
| Rosuvastatin Calcium | 63 | $536 |
| Carvedilol | 68 | $512 |
| Nifedipine ErNifedipine | 22 | $511 |
| Spironolactone | 37 | $270 |
| Potassium Chloride | 19 | $264 |
| Metoprolol Tartrate | 36 | $249 |
| Furosemide | 55 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $55,00265 claims |
| NovartisEntresto | $36 | $19,14524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Frisco
- Sibi ThomasFrisco$143K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.